Every 10-Q that OSR HEALTH INC (OSRH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OSRH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSRH filings page.
OSR Health, Inc., a healthcare holding company focused on immunotherapies, biologics and medical devices, reported substantially lower losses but sharply reduced revenue for the quarter and six months ended June 30, 2026. Net sales were $315,669 for the quarter and $799,727 for the first half of 2026, down 72% and 58% from the prior-year periods, largely reflecting a shift at subsidiary RMC from a purchase-and-resale model to a consignment, commission-based arrangement and prior one-time inventory sales.
Gross profit nonetheless improved, with quarterly gross margin rising from about 3% to 27%. Operating loss was $3.0 million for the quarter and $6.7 million year-to-date, both narrower than 2025, aided by lower SG&A and the absence of 2025 business-combination costs. Net loss attributable to OSR Health was $3.8 million for the first half. Total assets were $166.6 million and total liabilities $41.7 million.
Liquidity remains tight: cash and cash equivalents were $1.5 million, with $3.4 million of net cash used in operations in the first half. The company is relying on an $80 million equity line of credit, under which it has raised $3.38 million to date, and a 5% convertible note with a fixed $1.00 conversion price and a potential discounted alternative price if Nasdaq non-compliance is not cured. In June 2026, OSR announced a shareholder loyalty CVR program that may deliver up to 5 additional shares per share if specified price thresholds are met over 12 months. Management confirms ongoing material weaknesses in internal control over financial reporting, particularly around liabilities and accounting staffing, and states that remediation efforts are in progress.
OSR Holdings, Inc. (OSRH) filed its Q3 2025 10‑Q, showing continued operating losses alongside post‑merger integration and financing activity. For the three months ended September 30, 2025, net sales were $627,747 and gross profit was $261,734. Selling, general and administrative expenses were $4,065,199, leading to an operating loss of $3,803,465 and a net loss of $3,194,874; basic loss per share was $0.10. For the nine months ended September 30, 2025, net sales were $2,524,536 with an operating loss of $11,950,469 and a net loss of $19,812,886. Cash and cash equivalents were $2,177,309, and the accumulated deficit was $32,327,645.
After its February 14, 2025 business combination, the company reported total assets of $177,289,528 and stockholders’ equity of $134,157,845 as of September 30, 2025. OSRH entered an $80 million equity line of credit and, through September 30, 2025, issued 767,500 shares for gross proceeds of $741,937. The company received a Nasdaq minimum bid price deficiency notice with a grace period until March 4, 2026. Governance changes from the September 17, 2025 annual meeting included approval of an equity incentive plan and authority to exceed the 20% issuance limit under Nasdaq Rule 5635(d). A definitive agreement was signed for OSRK to acquire Woori IO Co., Ltd. for KRW15 billion (~$10.5 million), with a potential conversion into approximately 1.09 million OSRH shares if $10 per share is reached within three years.
OSR Holdings, Inc. (OSRH) completed a business combination in February 2025 and reported consolidated assets of $185.4 million and cash of $1.58 million as of June 30, 2025, up from $341,543 at December 31, 2024, including $1,219,888 received from the business combination. Intangible assets, principally patent technology, totaled $155.6 million and goodwill was $26.4 million.
Revenue from the medical-device distribution subsidiary increased to $1.14 million for the quarter, but gross profit fell sharply to $32,782 due to a supplier contract change and inventory returned under a consignment arrangement. Operating loss widened to $(5.23) million for the quarter and net loss for the six months was $(16.62) million, which included approximately $8.5 million of merger-related costs. Current liabilities rose to $15.86 million and a derivative liability of $630,603 was recorded. Recent disclosures include a July 2025 tokenization roadmap with BCM Europe AG and a signed term sheet to acquire Woori IO (noninvasive glucose monitoring), subject to due diligence and milestone-based share issuance.